There are five key areas of focus for the new platform

Develop an accessible high-throughput screening system with substantive small molecule and fractionated antimicrobial generating Natural Product libraries for antimicrobial, hygiene and household product discovery programmes, with backing from major pharma and North West-based consumer products companies.

Develop an accessible Category 3 based high-throughput whole cell screening system for intracellular infectious agents requiring high level containment and provide improved pharmacokinetic models for new molecules.

Provide access to safe and effective human challenge models. Alongside the other platforms, this will reduce the late stage failures in clinical trials, drastically reducing industries cost and time investments.

Use microwave and machine learning technologies generating an accessible platform to develop non-invasive diagnostics to quality assure disease prevention products and diagnose infections.

Improve the format and effectiveness of randomized control trials to reduce the time, complexity and cost of generating robust data to support international and country-based product approvals and registrations. Extending this post license to establish a model platform for assessing the optimal placement of products in settings where multiple interventions are used to tackle infection.